IGC Pharma Inc (IGC) - Price-to-Projected Revenue Ratio

Corporate company logo of IGC Pharma (IGC)

The forward P/S multiple reflects the valuation dynamics of IGC Pharma, Inc. (IGC) relative to expected revenues, with the value 16.50 representing the current figure. IGC Pharma, Inc. (IGC) faces financial threats driven by the legal instability of cannabis status and fierce competition. Stability is supported by the expansion of the patent portfolio and the development of Alzheimer's treatments. Growth is constrained by strict FDA and DEA oversight of ongoing trials.

IGC Pharma - IGC Forward Price to Sales (period 07/04/2022 - 11/15/2026)

Comprehensive metric breakdowns and analytics for India Globalization Capital (IGC)

- stock price and consensus target price:
Stock Quotes IGC Pharma, Inc.|IGC - Fair Value Consensus
- market capitalization indicators:
Market Value IGC Pharma|IGC - Full Business Value
- book value of equity indicators:
Book Value per Share IGC Pharma|IGC - Accounting Value of Company|Market Capitalization to Book Value Ratio igcinc.us|IGC - Company Total Assets
- debt burden and liquidity indicators:
Debt to Equity IGC Pharma, Inc.|IGC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity IGC Pharma, Inc.|IGC - Company Total Debt|Debts to Book Capitalization IGC Pharma|IGC - Company Long-Term Debts|Company Current Liabilities IGC Pharma|Quick Ratio igcinc.us
- financial results and valuation multiples details:
IGC - Net Financial Result|Expected Profit IGC Pharma, Inc.|IGC - Price to Earnings Multiple|Forward P/E Multiple IGC Pharma, Inc.|IGC - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio IGC Pharma Inc|IGC - Operating income before deduction of amortization|Net earnings per share (EPS TTM) IGC Pharma|IGC - Net earnings per share for the last four quarters|Quarterly EPS earnings growth igcinc.us|IGC - Net earnings per share change in current year|Earnings growth forecast for next year IGC Pharma, Inc.
- company sales and revenue statistics:
IGC - Company Sales|Company Projected Revenue igcinc.us|IGC - Market Cap to Revenue Ratio|Forward P/S Multiple IGC Pharma|IGC - Sales Growth YoY (TTM)
Analysis of all company metrics:IGC Pharma, Inc. IGC
Original product of IGC Pharma

The forward P/S ratio compares current market capitalization with expected revenue, reflecting the consensus valuation of the company's future cash flows. For IGC Pharma, Inc. (IGC), which is currently in a pre-commercial stage, changes in the forward P/S are critically sensitive to clinical trial success, as any stagnation in drug development amid a capital deficit could lead to a sharp devaluation of the business.

Competitors of IGC Pharma, Inc.

Forward P/S Multiple INDV (Indivior PLC)|Collegium Corp - Price-to-Projected Revenue Ratio|CRON - Price-to-Projected Revenue Ratio|Future Price to Revenue CGC|HITI (High Tide) - Forward Price-to-Revenue Multiple|Aurora Cannabis (ACB) - Forward P/S Multiple|Forward Price-to-Revenue Multiple ACHV|Price-to-Projected Revenue Ratio SKYE|Price-to-Projected Revenue Ratio Anebulo Pharmaceuticals Inc (ANEB)|Forward P/S Multiple InterCure Ltd (INCR)|Price-to-Projected Revenue Ratio nutriband.com NTRB|Forward Price to Sales NSRX|MIRA - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Flora Growth Corp.|IMCC: Forward P/S Multiple|Adial - Forward Price to Sales|Price-to-Projected Revenue Ratio Artelo Biosciences, Inc.|Market Cap to Future Revenue Ratio ensysce.com ENSC|Forward P/S Multiple TTNP|GNLN - Market Cap to Future Revenue Ratio|Forward P/S Multiple INM (InMed Pharmaceuticals Inc)|Forward Price to Sales AKAN|Enveric Biosciences Inc - Forward P/S Multiple|Projected Price to Revenue Bright Green Corp. (BGXX)|Hempacco Co., Inc. (HPCO) - Price-to-Projected Revenue Ratio